77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial

Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC. PMR-116 was developped as a second generation RiBi inhibitor in an effort to reduce potential non-specific DNA damage activity and therefore increase its tolerability and on-target activity.